Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 12:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,366 matching trials from the live ClinicalTrials.gov search.
Conditions
Schizophrenia
Interventions
Placebo, Luvadaxistat
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
216 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
33
States / cities
Phoenix, Arizona • Bentonville, Arkansas • Bryant, Arkansas + 24 more
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
Transcranial Alternating Current Stimulation (tACS), Sham Transcranial Alternating Current Stimulation
Device · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
45 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Cancer, Cognitive Impairment
Interventions
Behavioral: COPE +
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Depressive Symptoms, Depression, Alzheimer Disease, Mild Cognitive Impairment
Interventions
Psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 85 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
Alzheimer Disease
Interventions
F 18 T807
Drug
Lead sponsor
Tammie L. S. Benzinger, MD, PhD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Autism Spectrum Disorder, Pervasive Developmental Disorder, ASD, PDD
Interventions
Intranasal Oxytocin
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
12 Years to 55 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Cambridge, Massachusetts
Conditions
Cancer, Advanced, Cognitive Impairment, Mild
Interventions
Dyadic Life Review (DLR)
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
50 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Rochester, New York
Conditions
Post-Acute COVID-19, Post-Acute COVID-19 Syndrome, Post-Acute COVID-19 Infection, Long COVID, Long Covid19, Dyspnea, Orthostasis, Cognitive Impairment
Interventions
Comprehensive Rehabilitation, Augmented Usual Care
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
Not listed
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed Not applicable Interventional Accepts healthy volunteers Results available

Retrieval-Based Word Learning in Developmental Language Disorder During Book Reading II

NCT07048392
Conditions
Developmental Language Disorder and Language Impairment, Specific Language Impairment, Language Development
Interventions
Retrieval-based word learning: Repeated Spaced Retrieval condition, Retrieval-based word learning: Repeated Study condition
Behavioral
Lead sponsor
Purdue University
Other
Eligibility
48 Months to 71 Months
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
West Lafayette, Indiana
Recruiting No phase listed Observational Accepts healthy volunteers

OCT Angiography and NRAI in Dementia

NCT03761381
Conditions
Alzheimer Disease, Dementia, Mild Cognitive Impairment
Interventions
Optical Coherence Tomography Angiography (OCTA) Imaging, Noninvasive Retinal Amyloid Imaging (NRAI)
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Conditions
Mild Cognitive Impairment
Interventions
Neurofeedback, Placebo
Behavioral · Other
Lead sponsor
University of California, San Diego
Other
Eligibility
50 Years to 85 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
La Jolla, California
Completed Phase 2 Interventional Accepts healthy volunteers Results available

SNIFF Multi-Device Study 2

NCT04199767
Conditions
Mild Cognitive Impairment, Cognitive Impairment
Interventions
20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company), 40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 85 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

LEADing Dementia End-of-Life Planning Conversations

NCT05909189
Conditions
Alzheimer Disease, Mild Cognitive Impairment
Interventions
LEADing Dementia End-of-Life Planning Conversations
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of Florbetapir F 18 (18F-AV-45)

NCT01518374
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Neurodegenerative Diseases
Interventions
Florbetapir F 18
Drug
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,768 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2017
U.S. locations
26
States / cities
Phoenix, Arizona • Sun City, Arizona • Davis, California + 19 more
Conditions
Schizophrenia
Interventions
PF 03654746, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 40 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Completed No phase listed Observational Accepts healthy volunteers

COPD-Related Physiology and the Brain

NCT03269721
Conditions
Pulmonary Disease, Chronic Obstructive (COPD), Cognitive Impairment
Interventions
Neuropsychological Assessment, Spirometry, Arterial Blood Gas, Diffusion Capacity of the Lung for Carbon Monoxide, 6 Minute Walk Test, Systemic Vascular Measures, Blood Biomarkers, Symptom Questionnaire Measures, Brain MRI
Behavioral · Procedure · Diagnostic Test + 1 more
Lead sponsor
Karin Hoth
Other
Eligibility
30 Years to 85 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Aging, Mild Cognitive Impairment, Hypertension
Interventions
bpMedManage
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Tucson, Arizona • Champaign, Illinois
Conditions
Ischemic Stroke, Hypertension, Hyperlipidemias, Diabetes
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
50 participants
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Methylene Blue in Healthy Aging, Mild Cognitive Impairment and Alzheimer's Disease

NCT02380573
Conditions
Mild Cognitive Impairment, MCI, Aging, Alzheimer's Disease, AD
Interventions
Methylene Blue, FD&C Blue # 2, Phenazopyridine hydrochloride
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
45 Years to 89 Years
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2023
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Anxiety, Depression, Sleep Quality, Cognitive Impairment
Interventions
Low Dose MMFS-205-SR, High Dose MMFS-205-SR, Placebo
Dietary Supplement
Lead sponsor
Neurocentria, Inc.
Industry
Eligibility
60 Years to 85 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Springfield, Missouri
Completed No phase listed Observational Accepts healthy volunteers

Neurocognitive Outcomes of Depression in the Elderly

NCT00570583
Conditions
Major Depression, Dementia
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
60 Years and older
Enrollment
795 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Completed Phase 1 Interventional Accepts healthy volunteers

Standardized Field Test for Marijuana Impairment II

NCT05115513
Conditions
Marijuana Impairment
Interventions
Medium THC, Placebo THC
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Hartford, Connecticut
Completed Early Phase 1 Interventional Accepts healthy volunteers

High Confusion: Cannabis & Driving

NCT06236815
Conditions
Impairment, Cognitive, Impairment of Attention, Impairment, Psychomotor
Interventions
Delta-9-THC, Delta-8-THC, Placebo
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 49 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Mild Cognitive Impairment
Interventions
Kodro+, Kodro+D
Other
Lead sponsor
Mt. Sinai Medical Center, Miami
Other
Eligibility
60 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Miami Beach, Florida